what’s possible

By improving on past technologies, ADC Therapeutics has been able to engineer next-generation ADCs that are not only advancing in clinical trials, but also advancing what’s possible in cancer therapy.

Meet ADC Therapeutics

innovation

Proprietary PBD-based technology is the foundation for a robust pipeline of ADCs in the treatment of hematologic cancers and solid tumors.

See the Science

clinical trials

ADC Therapeutics is advancing novel PBD-based antibody drug conjugates through clinical development to improve patient outcomes in multiple oncology indications.

Explore the Pipeline

scientific knowledge

The exchange of information and resources with members of the medical community is critical in order to keep stakeholders abreast of the latest data and developments.

Discover the Resources